Varicella Zoster Virus Infections

 

Varicella Zoster Virus Infections

Richard J. Whitley

DEFINITION

Varicella-zoster virus (VZV) causes two distinct clinical entities: varicella (chickenpox) and herpes zoster (shingles). Chickenpox, a ubiquitous and extremely contagious infection, is usually a benign illness of childhood characterized by an exanthematous vesicular rash. With reactivation of latent VZV (which is most common after the sixth decade of life), herpes zoster presents as a dermatomal vesicular rash, usually associated with severe pain.

 

ETIOLOGY

A clinical association between varicella and herpes zoster has been recognized for nearly 100 years. Early in the twentieth century, similarities in the histopathologic features of skin lesions resulting from varicella and herpes zoster were demonstrated. Viral isolates from patients with chickenpox and herpes zoster produced similar alterations in tissue culture—specifically, the appearance of eosinophilic intranuclear inclusions and multinucleated giant cells. These results suggested that the viruses were biologically similar. Restriction endonuclease analyses of viral DNA from a patient with chickenpox who subsequently developed herpes zoster verified the molecular identity of the two viruses responsible for these different clinical presentations.

VZV is a member of the family Herpesviridae, sharing with other members such structural characteristics as a lipid envelope surrounding a nucleocapsid with icosahedral symmetry, a total diameter of ~180 to 200 nm, and centrally located double-stranded DNA that is ~125,000 bp in length.

PATHOGENESIS AND PATHOLOGY

Primary Infection

Transmission is most likely to take place by the respiratory route; the subsequent localized replication of the virus at an undefined site (presumably the nasopharynx) leads to seeding of the reticuloendothelial system and ultimately to the development of viremia. Viremia in patients with chickenpox is reflected in the diffuse and scattered nature of the skin lesions and can be verified in selected cases by the recovery of VZV from the blood or routinely by polymerase chain reaction (PCR). Vesicles involve the corium and dermis, with degenerative changes characterized by ballooning, the presence of multinucleated giant cells, and eosinophilic intranuclear inclusions. Infection may involve localized blood vessels of the skin, resulting in necrosis and epidermal hemorrhage. With the evolution of disease, the vesicular fluid becomes cloudy because of the recruitment of polymorphonuclear leukocytes and the presence of degenerated cells and fibrin. Ultimately, the vesicles either rupture and release their fluid (which includes infectious virus) or are gradually reabsorbed.

Recurrent Infection

The mechanism of reactivation of VZV that results in herpes zoster is unknown. Presumably, the virus infects the dorsal root ganglia during chickenpox, where it remains latent until reactivated. Histopathologic examination of representative dorsal root ganglia during active herpes zoster demonstrates hemorrhage, edema, and lymphocytic infiltration.

Active replication of VZV in other organs, such as the lung or the brain, can occur during either chickenpox or herpes zoster but is uncommon in the immunocompetent host. Pulmonary involvement is characterized by interstitial pneumonitis, multinucleated giant cell formation, intranuclear inclusions, and pulmonary hemorrhage. Central nervous system (CNS) infection leads to histopathologic evidence of perivascular cuffing similar to that encountered in measles and other viral encephalitides. Focal hemorrhagic necrosis of the brain, characteristic of herpes simplex virus encephalitis, is uncommon in VZV infection.

EPIDEMIOLOGY AND CLINICAL MANIFESTATIONS

Chickenpox

Humans are the only known reservoir for VZV. Chickenpox is highly contagious, with an attack rate of at least 90% among susceptible (seronegative) individuals. Persons of both sexes and all races are infected equally often. The virus is endemic in the population at large; however, it becomes epidemic among susceptible individuals during seasonal peaks—namely, late winter and early spring in the temperate zone. Historically, children between the ages of 5 and 9 are most commonly affected and account for 50% of all cases. Most other cases involve children aged 1 to 4 and those aged 10 to 14. Approximately 10% of the population of the United States over the age of 15 is susceptible to infection. VZV vaccination during the second year of life is dramatically changing the epidemiology of infection.

The incubation period of chickenpox ranges from 10 to 21 days but is usually between 14 and 17 days. Secondary attack rates in susceptible siblings within a household are between 70 and 90%. Patients are infectious ~48 h prior to the onset of the vesicular rash, during the period of vesicle formation (which generally lasts 4 to 5 days), and until all vesicles are crusted.

Clinically, chickenpox presents as a rash, low-grade fever, and malaise, although a few patients develop a prodrome 1 to 2 days before onset of the exanthem. In the immunocompetent patient, this is usually a benign illness that is associated with lassitude and with body temperatures of 37.8° to 39.4°C (100° to 103°F) of 3 to 5 days' duration. The skin lesions—the hallmark of the infection—include maculopapules, vesicles, and scabs in various stages of evolution. These lesions, which evolve from maculopapules to vesicles over hours to days, appear on the trunk and face and rapidly spread to involve other areas of the body. Most are small and have an erythematous base with a diameter of 5 to 10 mm. Successive crops appear over a 2- to 4-day period. Lesions can also be found on the mucosa of the pharynx and/or the vagina. Their severity varies from one person to another. Some individuals have very few lesions, while others have as many as 2000. Younger children tend to have fewer vesicles than older individuals. Secondary and tertiary cases within families are associated with a relatively large number of vesicles. Immunocompromised patients—both children and adults, particularly those with leukemia—have lesions (often with a hemorrhagic base) that are more numerous and take longer to heal than those of immunocompetent patients. Immunocompromised individuals are also at greater risk for visceral complications, which occur in 30 to 50% of cases and are fatal 15% of the time in the absence of antiviral therapy.

The most common infectious complication of varicella is secondary bacterial superinfection of the skin, which is usually caused by Streptococcus pyogenes or Staphylococcus aureus. This complication may result from excoriation of skin lesions after scratching. Gram's staining of skin lesions should help clarify the etiology of unusually erythematous and pustulated lesions.

The most common extracutaneous site of involvement in children is the CNS. The syndrome of acute cerebellar ataxia and meningeal irritation generally appears ~21 days after the onset of the rash and rarely develops in the preeruptive phase. The cerebrospinal fluid (CSF) contains lymphocytes and elevated levels of protein. CNS involvement is a benign complication of VZV infection in children and generally does not require hospitalization. Aseptic meningitis, encephalitis, transverse myelitis, Guillain-Barré syndrome, and Reye's syndrome can also occur. Encephalitis is reported in 0.1 to 0.2% of children with chickenpox. Other than supportive care, no specific therapy is available for patients with CNS involvement.

Varicella pneumonia is the most serious complication following chickenpox, developing more commonly in adults (up to 20% of cases) than in children. It usually has its onset 3 to 5 days into the illness and is associated with tachypnea, cough, dyspnea, and fever. Cyanosis, pleuritic chest pain, and hemoptysis are frequent. Roentgenographic evidence of disease consists of nodular infiltrates and interstitial pneumonitis. Resolution of pneumonitis parallels improvement of the skin rash; however, patients may have persistent fever and compromised pulmonary function for weeks.

Other complications of chickenpox include myocarditis, corneal lesions, nephritis, arthritis, bleeding diatheses, acute glomerulonephritis, and hepatitis. Hepatic involvement, distinct from Reye's syndrome and usually asymptomatic, is common in chickenpox and is generally characterized by elevated levels of liver enzymes, particularly aspartate and alanine aminotransferases.

Perinatal varicella is associated with a high mortality rate when maternal disease develops within 5 days before delivery or within 48 h thereafter. Because the newborn does not receive protective transplacental antibodies and has an immature immune system, the illness may be unusually severe. The reported mortality rate has been as high as 30% in this group. Congenital varicella, with clinical manifestations of limb hypoplasia, cicatricial skin lesions, and microcephaly at birth, is extremely uncommon.

Herpes Zoster

Herpes zoster, a sporadic disease, is the consequence of reactivation of latent VZV from the dorsal root ganglia. Most patients have no history of recent exposure to other individuals with VZV infection. Herpes zoster occurs at all ages, but its incidence is highest (5 to 10 cases per 1000 persons) among individuals in the sixth decade of life and beyond. Recurrent herpes zoster is exceedingly rare except in immunocompromised hosts, especially those with AIDS.

Herpes zoster, also called shingles, is characterized by a unilateral vesicular eruption within a dermatome, often associated with severe pain. The dermatomes from T3 to L3 are most frequently involved. If the ophthalmic branch of the trigeminal nerve is involved, zoster ophthalmicus results. The factors responsible for the reactivation of VZV are not known. In children reactivation is usually benign, whereas in adults it can be debilitating. The continuum of pain from onset to resolution is known as zoster-associated pain. The onset of disease is heralded by pain within the dermatome that may precede lesions by 48 to 72 h; an erythematous maculopapular rash evolves rapidly into vesicular lesions. In the normal host, these lesions may remain few in number and continue to form only for a period of 3 to 5 days. The total duration of disease is generally between 7 and 10 days; however, it may take as long as 2 to 4 weeks for the skin to return to normal. Patients with herpes zoster can transmit infection to seronegative individuals, with consequent chickenpox. In a few patients, characteristic localization of pain to a dermatome with serologic evidence of herpes zoster has been reported in the absence of skin lesions. When branches of the trigeminal nerve are involved, lesions may appear on the face, in the mouth, in the eye, or on the tongue. Zoster ophthalmicus is usually a debilitating condition that can result in blindness in the absence of antiviral therapy. In the Ramsay Hunt syndrome, pain and vesicles appear in the external auditory canal, and patients lose their sense of taste in the anterior two-thirds

of the tongue while developing ipsilateral facial palsy. The geniculate ganglion of the sensory branch of the facial nerve is involved.

The most debilitating complication of herpes zoster, in both the normal and the immunocompromised host, is pain associated with acute neuritis and postherpetic neuralgia. Postherpetic neuralgia is uncommon in young individuals; however, at least 50% of patients over age 50 with zoster report some degree of pain in the involved dermatome months after the resolution of cutaneous disease. Changes in sensation in the dermatome, resulting in either hypo- or hyperesthesia, are common.

CNS involvement may follow localized herpes zoster. Many patients without signs of meningeal irritation have CSF pleocytosis and moderately elevated levels of CSF protein. Symptomatic meningoencephalitis is characterized by headache, fever, photophobia, meningitis, and vomiting. A rare manifestation of CNS involvement is granulomatous angiitis with contralateral hemiplegia, which can be diagnosed by cerebral arteriography. Other neurologic manifestations include transverse myelitis with or without motor paralysis.

Like chickenpox, herpes zoster is more severe in the immunocompromised host than in the normal individual. Lesions continue to form for over a week, and scabbing is not complete in most cases until 3 weeks into the illness. Patients with Hodgkin's disease and non-Hodgkin's lymphoma are at greatest risk for progressive herpes zoster. Cutaneous dissemination develops in ~40% of these patients. Among patients with cutaneous dissemination, the risk of pneumonitis, meningoencephalitis, hepatitis, and other serious complications is increased by 5 to 10%. However, even in immunocompromised patients, disseminated zoster is rarely fatal.

Patients who have received a bone marrow transplant are at particularly high risk of VZV infection. Thirty percent of cases of posttransplantation VZV infection occur within 1 year (50% of these within 9 months); 45% of the patients involved have cutaneous or visceral dissemination. The mortality rate in this situation is 10%. Postherpetic neuralgia, scarring, and bacterial superinfection are especially frequent in VZV infections occurring within 9 months of transplantation. Among infected patients, concomitant graft-versus-host disease increases the chance of dissemination and/or death.

DIFFERENTIAL DIAGNOSIS

The diagnosis of chickenpox is not difficult. The characteristic rash and a history of recent exposure should lead to a prompt diagnosis. Other viral infections that can mimic chickenpox include disseminated herpes simplex virus infection in patients with atopic dermatitis and the disseminated vesiculopapular lesions sometimes associated with coxsackievirus infection, echovirus infection, or atypical measles. However, these rashes are more commonly morbilliform with a hemorrhagic component rather than vesicular or vesiculopustular. Rickettsialpox can be confused with chickenpox; however, it can be distinguished easily by detection of the “herald spot” at the site of the mite bite and the development of a more pronounced headache. Serologic testing is also useful in differentiating rickettsialpox from varicella. Concern about smallpox has recently increased because of the threat of bioterrorism. The lesions of smallpox are larger than those of chickenpox and are all at the same stage of evolution.

Unilateral vesicular lesions in a dermatomal pattern should lead rapidly to the diagnosis of herpes zoster, although the occurrence of shingles without a rash has been reported. Both herpes simplex virus infections and coxsackievirus infections can cause dermatomal vesicular lesions. Supportive diagnostic virology and fluorescent staining of skin scrapings with monoclonal antibodies are helpful in ensuring the proper diagnosis. In the prodromal stage of herpes zoster, the diagnosis can be exceedingly difficult and may be made only after lesions have appeared or by retrospective serologic assessment.

LABORATORY FINDINGS

Unequivocal confirmation of the diagnosis is possible only through the isolation of VZV in susceptible tissue-culture cell lines, the demonstration of either seroconversion or a fourfold or greater rise in antibody titer between convalescent- and acute-phase serum specimens, or the detection of VZV DNA by PCR. A rapid impression can be obtained by a Tzanck smear, with scraping of the base of the lesions in an attempt to demonstrate multinucleated giant cells, although the sensitivity of this method is low (~60%). PCR technology for the detection of viral DNA in vesicular fluid is available in a limited number of diagnostic laboratories. Direct immunofluorescent staining of cells from the lesion base or detection of viral antigens by other assays (such as the immunoperoxidase assay) is also useful, although these tests are not commercially available. The most frequently employed serologic tools for assessing host response are the immunofluorescent detection of antibodies to VZV membrane antigens, the fluorescent antibody to membrane antigen (FAMA) test, immune adherence hemagglutination, and enzyme-linked immunosorbent assay (ELISA). The FAMA test and the ELISA appear to be the most sensitive.

TREATMENT

Medical management of chickenpox in the immunologically normal host is directed toward the prevention of avoidable complications. Obviously, good hygiene includes daily bathing and soaks. Secondary bacterial infection of the skin can be avoided by meticulous skin care, particularly with close cropping of fingernails. Pruritus can be decreased with topical dressings or the administration of antipruritic drugs. Tepid water baths and wet compresses are better than drying lotions for the relief of itching. Aluminum acetate soaks for the management of herpes zoster can be both soothing and cleansing. Administration of aspirin to children with chickenpox should be avoided because of the association of aspirin derivatives with the development of Reye's syndrome. Acyclovir therapy (800 mg by mouth five times daily for 5 to 7 days) is recommended for adolescents and adults with chickenpox of ≤24 h duration. Likewise, acyclovir therapy may be of benefit to children <12 years of age if initiated early in the disease (<24 h) at a dose of 20 mg/kg every 6 h.

Patients with herpes zoster benefit from oral antiviral therapy, as evidenced by accelerated healing of lesions and resolution of zoster-associated pain with acyclovir, valacyclovir, or famciclovir. Acyclovir, now off patent, is administered at a dosage of 800 mg five times daily for 7 to 10 days. Famciclovir, the prodrug of penciclovir, is at least as effective as acyclovir and perhaps more so. One study showed twofold faster resolution of postherpetic neuralgia in famciclovir-treated patients with zoster than in recipients of placebo. The dose is 500 mg by mouth three times daily for 7 days. Valacyclovir, the prodrug of acyclovir, accelerates healing and resolution of zoster-associated pain more promptly than acyclovir. The dose is 1 g by mouth three times daily for 5 to 7 days. Both famciclovir and valacyclovir offer the advantage of a lower dosing frequency than acyclovir.

In the immunocompromised host, both chickenpox and herpes zoster (including disseminated disease) should be treated with intravenous acyclovir, which reduces the occurrence of visceral complications but has no effect on healing of skin lesions or pain. The dose is 10 to 12.5 mg/kg every 8 h for 7 days. Oral acyclovir therapy is not recommended for the treatment of VZV infections in immunocompromised patients. Concomitant with the administration of intravenous acyclovir, it is desirable to attempt to wean these patients from immunosuppressive treatment.

Patients with varicella pneumonia may require removal of bronchial secretions and ventilatory support. Persons with zoster ophthalmicus should be referred immediately to an ophthalmologist. Therapy for this condition consists of the administration of analgesics for severe pain and the use of atropine. Acyclovir accelerates healing.

The management of acute neuritis and/or postherpetic neuralgia can be particularly difficult. In addition to the judicious use of analgesics, ranging from nonnarcotics to narcotic derivatives, drugs such as gabapentin, amitriptyline hydrochloride, lidocaine patches, and fluphenazine hydrochloride have been reported to be beneficial for pain relief. In one study, glucocorticoid therapy administered early in the course of localized herpes zoster significantly accelerated such quality-of-life improvements as a return to usual activity and termination of analgesia. The dose of prednisone administered orally was 60 mg/d on days 1 through 7, 30 mg/d on days 8 through 14, and 15 mg/d on days 15 through 21. This regimen is appropriate only for relatively healthy elderly persons who have moderate or severe pain at presentation. Patients with osteoporosis, diabetes mellitus, glycosuria, or hypertension may not be appropriate candidates. Glucocorticoids should not be used without concomitant antiviral therapy.

PREVENTION

Three methods are used for the prevention of VZV infections. First, a live attenuated varicella vaccine (OKA) is recommended for all children >1 year of age (up to 12 years of age) who have not had chickenpox and for adults known to be seronegative for VZV. A single dose of vaccine is administered to children, whereas adults require two doses. The vaccine is both safe and efficacious. Breakthrough cases are mild and may result in spread of the vaccine virus to susceptible contacts. The universal vaccination of children is resulting in a decreased incidence of chickenpox in sentinel communities. Furthermore, inactivation of the vaccine virus significantly decreases the occurrence of herpes zoster after human stem-cell transplantation. A vaccine study is being performed in individuals >60 years of age to determine its impact on the incidence and severity of shingles.

A second approach is to administer varicella-zoster immune globulin (VZIg) to individuals who are susceptible, are at high risk for developing complications of varicella, and have had a significant exposure. This product should be given within 96 h (preferably within 72 h) of the exposure. Indications for administration of VZIg appear in Table1.

TABLE 1 Recommendations for VZIg Administration


 

Exposure criteria

1.

Exposure to person with chickenpox or zoster

 

a.

Household: residence in the same household

 

b.

Playmate: face-to-face indoor play

 

c.

Hospital
Varicella: same 2- to 4-bed room or adjacent beds in large ward, face-to-face contact with infectious staff member or patient, visit by a person deemed contagiousZoster: intimate contact (e.g., touching or hugging) with a person deemed contagious

 

d.

Newborn infant: onset of varicella in the mother ≤5 days before delivery or ≤48 h after delivery; VZIg is not indicated if the mother has zoster

2.

Patient should receive VZIg as soon as possible but not >96 h after exposure

Candidates (provided they have significant exposure) include:

1.

Immunocompromised susceptible children without history of varicella or varicella immunization

2.

Susceptible pregnant women

3.

Newborn infants whose mother had onset of chickenpox within 5 days before or within 48 h after delivery

4.

Hospitalized premature infant (≥28 weeks of gestation) whose mother lacks a reliable history of chickenpox or serologic evidence of protection against varicella

5.

Hospitalized premature infant (<28 weeks of gestation or ≤1000-g birth weight), regardless of maternal history of varicella or varicella-zoster virus serologic status


 

Lastly, antiviral therapy can be given as prophylaxis to individuals at high risk who are ineligible for vaccine or beyond the 96-h window after direct contact. While the initial studies have used acyclovir, similar benefit can be anticipated with either valacyclovir or famciclovir. Therapy is instituted 7 days after intense exposure. At this time, the host is midway into the incubation period. This approach significantly decreases disease severity, if not totally preventing disease.

 

 

Bạn đang ở: Home Tài liệu Varicella Zoster Virus Infections